Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model.

Siebren Dijkstra, Tim M Govers, Rianne J Hendriks, Jack A Schalken, Wim Van Criekinge, Leander Van Neste, Janneke P C Grutters, J P Michiel Sedelaar, Inge M van Oort,

BJU international, April 3, 2017

To assess the cost-effectiveness of a new urinary biomarker-based risk score (SelectMDx) to identify patients for transrectal ultrasound-guided biopsy (TRUSGB) and to compare this with the current standard of care (SOC), using only prostate-specific antigen (PSA) to select for TRUSGB. A decision tree and Markov model were developed to evaluate the cost-effectiveness of SelectMDx as a reflex test versus SOC in men with a PSA >3 ng/ml. Transition probabilities, utilities and costs were derived from literature and expert opinion. Cost-effectiveness was expressed in quality-adjusted life years (QALYs) and healthcare costs of both diagnostic strategies, simulating the course of patients over a time horizon representing 18 years. Deterministic sensitivity analyses were performed to address uncertainty in assumptions. A diagnostic strategy including SelectMDx with a cut-off chosen at a sensitivity of 95.7% for high-grade PCa resulted in savings of €128 and a gain of 0.025 QALY per patient compared to the SOC strategy. The sensitivity analyses demonstrated that the disutility assigned to active surveillance had a high impact on the QALYs gained and the disutility attributed to TRUSGB only slightly influenced the outcome of the model. Based on the currently available evidence, the reduction of overdiagnosis and overtreatment due to the use of the SelectMDx test in men with PSA>3 ng/ml may lead to a reduction in total costs per patient and a gain in QALYs. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.

Pubmed Link: 28370948

DOI: 10.1111/bju.13861